146
Participants
Start Date
February 29, 2016
Primary Completion Date
March 20, 2020
Study Completion Date
October 17, 2022
IMCgp100
Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Columbia University Medical Center - The New York Presbyterian Hospital, New York
Memorial Sloan Kettering Hospital, New York
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin
Roswell Park Cancer Institute, Buffalo
Thomas Jefferson University Medical Oncology Clinic, Philadelphia
Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
Hospital Universitario La Paz, Madrid
University of Miami Hospital Clinics/Sylvester Comprehensive Cancer Center, Miami
Vanderbilt University Medical Center, Nashville
Hospital Universitario Virgen Macarena, Seville
Hospital General Universitario de Valencia, Valencia
The University of Chicago Medical Center, Chicago
Washington University, School of Medicine, St Louis
Universitaetsklinikum Heidelberg, Heidelberg
Dean A. Mcgee Eye Institute, Oklahoma City
Baylor Scott & White Health, Temple
University of Colorado Denver Anschutz Medical Campus, Aurora
The Angeles Clinic and Research Institute - W LA Office, Los Angeles
University California, San Diego Moores Cancer Center, La Jolla
California Pacific Medical Center, San Francisco
Providence Portland Medical Center, Portland
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa
Princess Margaret Cancer Center, Toronto
ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat
The Clatterbridge Cancer Centre, Metropolitan Borough of Wirral
Mount Vernon Cancer Centre, Northwood
Lead Sponsor
Immunocore Ltd
INDUSTRY